Back to Agenda
Europe on the Biopharmaceutical Innovation Map
Session Chair(s)
Magda Chlebus, MA
Executive Director, Science Policy & Regulatory Affairs
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Europeans are facing decreased access to new medicines and the ability to take part in ground-breaking clinical trials, as research and development of new treatments increasingly moves to more ambitious life science sectors in the US and Asia: • R&D investment: In 2002 the US spent $2billion more than Europe on R&D; today that figure is $25billion - a rise of 1000%. Of the total R&D investments made in the US, Europe, China and Japan, only 31% of this occurs in Europe. This has declined steadily from 41% in 2001. China has meanwhile grown its share from 1% to 8%. • ATMPs: Clinical trial activity is twice as high in the US and almost three times as high in China than in Europe. The number of ATMP trials conducted in the US and Asia-Pacific region grew by 70% and 67%, respectively from 2014-21, while Europe remained stagnant. • Clinical trials: Europe accounted for a 19.3% share of global clinical trials activity in 2020, a decrease of 6.3%, compared with a 25.6% average over the last ten-years. Decisions regarding investment in research hubs and manufacturing are long-term decisions, while clinical trials are often carried out over many years. For Europe to be strategically autonomous from the rest of the world it requires a vibrant R&D ecosystem. The policy decisions taken today will impact on Europe’s attractiveness for investment for decades to come. The session will bring together key players in the pharmaceutical innovation from investors, developers, health and regulatory authorities, patients to discuss Europe’s ambition for pharmaceutical innovation, components of a successful innovation environment, and how to create it in Europe using the momentum of the pharmaceutical strategy.
Learning Objective : Objectives of this DIAMON session: - Discuss key stakeholders and policymakers' vision for pharmaceutical innovation in Europe - Identify factors affecting the location of biopharmaceutical investments and key components of an attractive and successful innovation environment and its enablers
Speaker(s)
How Europe Can Regain Competitive Advantage in Approving Innovative Medicines?
Pedro Franco, PharmD, PhD, MS, MSc
Merck Serono Limited, United Kingdom
Senior Director for Global Regulatory & Scientific Policy (GRASP)
![Ferenc Marofka](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Ferenc Marofka
European Commission, Belgium
Policy Officer Health Medecines
![Virginie Hivert, PharmD, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Virginie Hivert, PharmD, PhD
Eurordis-Rare Diseases Europe, France
Therapeutic Development Director
Panelist
Steffen Thirstrup, MD, PhD
European Medicines Agency, Netherlands
Chief Medical Officer
![Katharina Nothelfer](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Katharina Nothelfer
AiCuris, Germany
Director, Strategic Communications
![Annette Bakker, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Annette Bakker, PhD
Children's Tumor Foundation and CTF Europe, United States
President and Chair of the board
![Jeevan Virk](/_Images/member/Generic_Image_Missing-Profile.jpg)
Jeevan Virk
Novartis, Switzerland
Radioligand Therapy (RLT) Therapeutic Area Strategy Head
Have an account?